Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Mayo Clinic
The Christie NHS Foundation Trust
Dragonfly Therapeutics
Dragonfly Therapeutics
Immunocore Ltd
Seagen Inc.
AI Labs Group S.L
BioNTech SE
Dana-Farber Cancer Institute
Emory University
Institute of Oncology Ljubljana
Endeavor Biomedicines, Inc.
Hasumi International Research Foundation
Institute of Oncology Ljubljana
Pfizer
Melanoma Institute Australia
H. Lee Moffitt Cancer Center and Research Institute
Amgen
San Gallicano Dermatological Institute IRCCS
Bristol-Myers Squibb
Institute of Oncology Ljubljana
AI Labs Group S.L
AI Labs Group S.L
AI Labs Group S.L
Institute of Oncology Ljubljana
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
Amgen
Adaptimmune
Hoffmann-La Roche
Wake Forest University Health Sciences
University of Wisconsin, Madison
Beth Israel Deaconess Medical Center
CHU de Reims
InxMed (Shanghai) Co., Ltd.
Rutgers, The State University of New Jersey
Daiichi Sankyo
Pierre Fabre Medicament
M.D. Anderson Cancer Center
BioNTech SE
Memorial Sloan Kettering Cancer Center
Indiana University
Thomas Jefferson University
University Hospital, Tours
Swiss Cancer Institute
Pharmassist Ltd
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC